• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury.因子 H 与管状上皮细胞的结合限制了缺血性损伤中间质补体的激活。
Kidney Int. 2011 Jul;80(2):165-73. doi: 10.1038/ki.2011.115. Epub 2011 May 4.
2
Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM.补体因子 H 可保护小鼠免于缺血性急性肾损伤,但对于控制肾小球 IgM 激活补体并非关键。
Eur J Immunol. 2018 May;48(5):791-802. doi: 10.1002/eji.201747240. Epub 2018 Feb 22.
3
Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion.补体抑制剂Crry的肾小管表达改变会导致缺血/再灌注后补体激活。
J Clin Invest. 2006 Feb;116(2):357-68. doi: 10.1172/JCI24521. Epub 2006 Jan 26.
4
The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells.补体抑制剂 Crry 和因子 H 对于防止肾管状上皮细胞的自身补体激活至关重要。
J Immunol. 2010 Sep 1;185(5):3086-94. doi: 10.4049/jimmunol.1000111. Epub 2010 Jul 30.
5
C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion.肾缺血/再灌注后,肾小管上皮细胞产生CXC趋化因子需要C3a。
J Immunol. 2007 Feb 1;178(3):1819-28. doi: 10.4049/jimmunol.178.3.1819.
6
Complement activation and toll-like receptor-2 signaling contribute to cytokine production after renal ischemia/reperfusion.补体激活和 Toll 样受体 2 信号通路参与肾缺血再灌注后细胞因子的产生。
Mol Immunol. 2012 Oct;52(3-4):249-57. doi: 10.1016/j.molimm.2012.05.020. Epub 2012 Jun 27.
7
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.一种新型补体替代途径靶向抑制剂及其在缺血/再灌注损伤中的治疗应用。
J Immunol. 2008 Dec 1;181(11):8068-76. doi: 10.4049/jimmunol.181.11.8068.
8
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice.缺乏功能性替代补体途径可改善小鼠缺血性急性肾衰竭。
J Immunol. 2003 Feb 1;170(3):1517-23. doi: 10.4049/jimmunol.170.3.1517.
9
Uromodulin aggravates renal tubulointerstitial injury through activation of the complement pathway in rats.尿调蛋白通过激活大鼠补体途径加重肾间质小管损伤。
J Cell Physiol. 2021 Jul;236(7):5012-5021. doi: 10.1002/jcp.30208. Epub 2021 Jan 5.
10
The C5a/C5aR1 axis promotes progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia/reperfusion injury.C5a/C5aR1 轴促进了肾缺血/再灌注损伤小鼠模型肾小管间质纤维化的进展。
Kidney Int. 2019 Jul;96(1):117-128. doi: 10.1016/j.kint.2019.01.039. Epub 2019 Mar 4.

引用本文的文献

1
Exploring Potential Complement Modulation Strategies for Ischemia-Reperfusion Injury in Kidney Transplantation.探索肾移植中缺血再灌注损伤的潜在补体调节策略。
Antioxidants (Basel). 2025 Jan 8;14(1):66. doi: 10.3390/antiox14010066.
2
Factor H related proteins modulate complement activation on kidney cells.补体因子 H 相关蛋白调节肾脏细胞的补体激活。
Kidney Int. 2022 Dec;102(6):1331-1344. doi: 10.1016/j.kint.2022.07.035. Epub 2022 Sep 3.
3
Extracellular vesicles derived from patients with antibody-mediated rejection induce tubular senescence and endothelial to mesenchymal transition in renal cells.来源于抗体介导排斥反应患者的细胞外囊泡诱导肾小管衰老和内皮细胞向间充质转化。
Am J Transplant. 2022 Sep;22(9):2139-2157. doi: 10.1111/ajt.17097. Epub 2022 Jul 5.
4
Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application.补体系统在肾移植中的作用:从动物模型到临床应用的进展。
Front Immunol. 2022 Feb 25;13:811696. doi: 10.3389/fimmu.2022.811696. eCollection 2022.
5
Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.肾脏疾病与补体的作用:将补体与免疫效应途径和治疗联系起来。
Adv Immunol. 2021;152:1-81. doi: 10.1016/bs.ai.2021.09.001. Epub 2021 Nov 19.
6
Activation of final complement components after kidney transplantation as a marker of delayed graft function severity.肾移植后终末补体成分的激活作为移植肾功能延迟严重程度的标志物。
Clin Kidney J. 2020 Oct 10;14(4):1190-1196. doi: 10.1093/ckj/sfaa147. eCollection 2021 Apr.
7
Role of C5aR1 and C5L2 Receptors in Ischemia-Reperfusion Injury.C5aR1和C5L2受体在缺血再灌注损伤中的作用。
J Clin Med. 2021 Mar 2;10(5):974. doi: 10.3390/jcm10050974.
8
The importance of sialic acid, pH and ion concentration on the interaction of uromodulin and complement factor H.唾液酸、pH 值和离子浓度对尿调蛋白与补体因子 H 相互作用的重要性。
J Cell Mol Med. 2021 May;25(9):4316-4325. doi: 10.1111/jcmm.16492. Epub 2021 Mar 31.
9
Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis.循环 FH 可防止全身性溶血性肾小管损伤。
Front Immunol. 2020 Aug 7;11:1772. doi: 10.3389/fimmu.2020.01772. eCollection 2020.
10
Donor Urinary C5a Levels Independently Correlate With Posttransplant Delayed Graft Function.供者尿 C5a 水平与移植后延迟肾功能恢复独立相关。
Transplantation. 2019 Jan;103(1):e29-e35. doi: 10.1097/TP.0000000000002494.

本文引用的文献

1
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.一种新型补体替代途径靶向抑制剂及其在缺血/再灌注损伤中的治疗应用。
J Immunol. 2008 Dec 1;181(11):8068-76. doi: 10.4049/jimmunol.181.11.8068.
2
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice.在缺乏补体因子H的小鼠中,补体因子I是膜增生性肾小球肾炎发生所必需的。
J Clin Invest. 2008 Feb;118(2):608-18. doi: 10.1172/JCI32525.
3
New approaches to the treatment of dense deposit disease.治疗致密物沉积病的新方法。
J Am Soc Nephrol. 2007 Sep;18(9):2447-56. doi: 10.1681/ASN.2007030356. Epub 2007 Aug 5.
4
Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes.补体调节蛋白H介导的细胞表面补体保护作用对阵发性睡眠性血红蛋白尿症(PNH)红细胞的存活至关重要。
Blood. 2007 Sep 15;110(6):2190-2. doi: 10.1182/blood-2007-04-083170. Epub 2007 Jun 6.
5
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.由缺乏表面识别结构域的补体因子H引发的自发性溶血尿毒综合征。
J Exp Med. 2007 Jun 11;204(6):1249-56. doi: 10.1084/jem.20070301. Epub 2007 May 21.
6
The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells.与年龄相关性黄斑变性相关的因子H变体(His-384)和非疾病相关形式与C反应蛋白、纤维调节蛋白、DNA和坏死细胞的结合存在差异。
J Biol Chem. 2007 Apr 13;282(15):10894-900. doi: 10.1074/jbc.M610256200. Epub 2007 Feb 9.
7
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.抗中性粒细胞胞浆自身抗体介导疾病发病机制中的替代补体途径。
Am J Pathol. 2007 Jan;170(1):52-64. doi: 10.2353/ajpath.2007.060573.
8
Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces.补体因子H的C末端结构域在调节细胞表面补体激活中的关键作用。
J Immunol. 2006 Nov 1;177(9):6308-16. doi: 10.4049/jimmunol.177.9.6308.
9
The simple design of complement factor H: Looks can be deceiving.补体因子H的简单设计:表象可能具有欺骗性。
Mol Immunol. 2007 Jan;44(1-3):123-32. doi: 10.1016/j.molimm.2006.07.287. Epub 2006 Aug 17.
10
Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury.用针对小鼠补体因子B的抑制性单克隆抗体进行治疗,可保护小鼠免受细胞凋亡诱导以及肾缺血/再灌注损伤。
J Am Soc Nephrol. 2006 Mar;17(3):707-15. doi: 10.1681/ASN.2005070698. Epub 2006 Feb 8.

因子 H 与管状上皮细胞的结合限制了缺血性损伤中间质补体的激活。

Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury.

机构信息

Department of Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA.

出版信息

Kidney Int. 2011 Jul;80(2):165-73. doi: 10.1038/ki.2011.115. Epub 2011 May 4.

DOI:10.1038/ki.2011.115
PMID:21544060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3133686/
Abstract

Factor H is a regulator of the alternative pathway of complement, and genetic studies have shown that patients with mutations in factor H are at increased risk for several types of renal disease. Pathogenic activation of the alternative pathway in acquired diseases, such as ischemic acute kidney injury, suggests that native factor H has a limited capacity to control the alternative pathway in the kidney. Here we found that an absolute deficiency of factor H produced by gene deletion prevented complement activation on tubulointerstitial cells after ischemia/reperfusion (I/R) injury, likely because alternative pathway proteins were consumed in the fluid phase. In contrast, when fluid-phase regulation by factor H was maintained while the interaction of factor H with cell surfaces was blocked by a recombinant inhibitor protein, complement activation after renal I/R increased. Finally, a recombinant form of factor H, specifically targeted to sites of C3 deposition, reduced complement activation in the tubulointerstitium after ischemic injury. Thus, although factor H does not fully prevent activation of the alternative pathway of complement on ischemic tubules, its interaction with the tubule epithelial cell surface is critical for limiting complement activation and attenuating renal injury after ischemia.

摘要

因子 H 是补体替代途径的调节因子,遗传研究表明,因子 H 突变的患者患几种类型的肾脏疾病的风险增加。在获得性疾病(如缺血性急性肾损伤)中,替代途径的致病性激活表明,天然因子 H 控制肾脏替代途径的能力有限。在这里,我们发现基因缺失导致的因子 H 绝对缺乏可防止缺血/再灌注 (I/R) 损伤后小管间质性细胞的补体激活,可能是因为替代途径蛋白在液相中被消耗。相比之下,当通过因子 H 维持液相调节,同时通过重组抑制剂蛋白阻断因子 H 与细胞表面的相互作用时,肾 I/R 后的补体激活增加。最后,一种针对 C3 沉积部位的因子 H 重组形式可减少缺血性损伤后小管间质性中的补体激活。因此,尽管因子 H 不能完全防止缺血小管替代途径补体的激活,但它与肾小管上皮细胞表面的相互作用对于限制补体激活和减轻缺血后肾脏损伤至关重要。